Key result
tPA shows no functional benefit over aspirin in minor acute ischemic stroke.
Why the study?
Direct randomized controlled trial evidence comparing the efficacy and safety of tPA versus aspirin in broader acute ischemic stroke populations is limited.
Does tissue plasminogen activator (tPA) improve functional outcomes compared to aspirin in patients with acute ischemic stroke?
Does tissue plasminogen activator (tPA) improve functional outcomes compared to aspirin in patients with acute ischemic stroke?
Current evidence from systematic reviews and meta-analyses shows no significant difference in functional outcomes between tPA and aspirin for minor acute ischemic strokes, though aspirin has a trend toward lower symptomatic hemorrhage and direct RCTs in broader populations are lacking.
Current evidence from systematic reviews and meta-analyses indicates no significant difference in functional outcomes between tPA and aspirin for minor strokes, with aspirin having a lower trend in symptomatic hemorrhage. However, direct RCTs specifically designed to compare these treatments in broader acute ischemic stroke populations are limited.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. tPA and aspirin show no significant difference in functional outcomes for minor acute ischemic strokes, though aspirin trends toward lower symptomatic hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: